Peter H. Krammer

Peter H. Krammer (born April 2, 1946 in Rheydt ) is a German immunologist who is particularly known for research on apoptosis .

Life

Until 1971, Krammer studied medicine at the Albert Ludwig University of Freiburg , in St. Louis and Lausanne . From 1973 to 1975 he was a scientific member of the Basel Institute for Immunology . From 1976 he was at the Max Planck Institute for Immunology in Freiburg, since 1976 at the German Cancer Research Center (DKFZ) in Heidelberg and later professor at the Medical Faculty of Heidelberg University. In 1981 he was visiting professor at the University of Texas (Health Science Center) in Dallas . In 1984/85 he was a visiting scientist at the Center for Molecular Biology in Heidelberg . From 1981 he headed the Department of Immunogenetics at the DKFZ, from 1990 he was director of the Institute for Immunology and Genetics at the DKFZ and from 1993 spokesman for the research focus on tumor immunology. Since 2008 he has headed the Helmholtz Alliance Immunotherapy of Cancer of the Helmholtz Association . In addition, he has been on the board of directors of the National Center for Tumor Diseases (NCT) for several years .

Krammer researched the mechanisms of programmed cell death (apoptosis) and is involved in the development of drugs based on it, for example against cancer (cancer cells have developed mechanisms to avoid apoptosis). In 2000 he was one of the founders of Apogenix, a pharmaceutical research spin-off from the DKFZ, with Henning Walczak (his former doctoral student).

In 1989, Krammer and his team discovered the CD95 receptor (APO-1, Fas) and other molecules involved in the CD95 signaling pathway. Apoptosis plays an important role in the self-control of the immune system, but cancer cells also use it for growth and invasion or to defend themselves against immune cells by specifically triggering their apoptosis (tumor counterattack). Krammer is also studying the role of CD95 in autoimmune diseases.

He is a member of EMBO, Leopoldina , Academia Europaea and, since 2009, of the Heidelberg Academy of Sciences .

Selection of prizes and awards

1991 Kind Phillip Award for Leukemia Research
1995 Behring Lecture
1995 Robert Koch Prize with Shigekazu Nagata , for fundamental work on apoptosis
1996 German Cancer Prize
1996 Kitasato Behring Prize
1996 Heinz Ansmann Prize
1996 Meyenburg Prize
1996 Cross of Merit 1st Class of the Federal Republic of Germany
1997 Cancer Research Award Wilhelm Warner Foundation
1998 Avery Landsteiner Prize
2000 Ernst Jung Prize for Medicine
2000 Norman Heatley Lecture Oxford
2000 Ludwik Hirszfeld Prize of the Polish Society for Immunology
2000 Theodor Kocher Lecture, Düsseldorf
2001 Genius Biotech Award for the Apogenix company
2003 Lautenschläger research award
2004 First International Cell Death Society Prize
2011 German Cancer Aid Prize
2012 Johann Georg Zimmermann Medal

Fonts

Apoptosis in the immune system: murder or suicide . In: Pharmacy in our time , Volume 25, 1996, p. 306 (Lecture on the occasion of the receipt of the Robert Koch Prize)
CD 95's deadly mission in the immune system . In: Nature , Volume 407, 2000, p. 789
with Muzio, Chinnaiyan, Kischkel, O'Rourke, Shevchenko, Ni, Scaffidi, Bretz, Zhang, Gentz, Mann, Peter, Dixit: FLICE- a novel FADD homologous ICE / CED-3-like protease, is recruited to the CD 95 (FAS / APO-1) death inducing signaling complex . In: Cell , Vol. 85, 1996, pp. 817-827
with Dhein, Walczak, Bäumler, Debatin Autocrine T-cell suicide mediated by APO-1 / (FAS / CD 95) . In: Nature , Volume 373, 1995, pp. 438-441
with Westendorp, Frank, Stricker, Dhein, Debatin, Walczak Sensitization fo T-cells to CD-95 mediated apoptosis by HIV-1 Tat and gp120 . In: Nature , Volume 375, 1995, pp. 497-500
with Trauth, Klas, Peters, Matzku, Möller, Falk, Debatin: Monoclonal antibody mediated tumor regression by induction of apoptosis . In: Science , Vol. 245, 1989, pp. 301-305

Web links

CV (PDF) at the DKFZ
Krammer at the NCT

Individual evidence

^ ^A ^b German Academy of Sciences Leopoldina - Newly elected members 2004 . (PDF; 1.58 MB) Halle (Saale), p. 45.
↑ Trauth, Klas, Peters Matzku, Möller, Falk, Debatin, Krammer: Monoclonal antibody-mediated tumor regression by induction of apoptosis . In: Science , Vol. 245, 1989, pp. 301-305, PMID 2787530 .
^ The associated Fas ligand was cloned in 1993: Suda, Takahashi, Golstein, Nagata: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family . In: Cell , Vol. 75, 1993, pp. 1169-1178
↑ Krammer: Cd95s deathly mission in the immune system . In: Nature , Volume 407, 2000, pp. 789-795
^ FH Igney, PH Krammer: Tumor counterattack: fact or fiction? In: Cancer Immunol Immunother . , 54 (11), 2005, pp. 1127-1136
↑ Member entry by Peter H. Krammer (with picture and CV) at the German Academy of Natural Scientists Leopoldina , accessed on July 17, 2016.
↑ Directory of members: Peter H. Krammer. Academia Europaea, accessed July 3, 2017 .

personal data
SURNAME	Krammer, Peter H.
BRIEF DESCRIPTION	German immunologist
DATE OF BIRTH	April 2, 1946
PLACE OF BIRTH	Rheydt

[leo-1] A ^b German Academy of Sciences Leopoldina - Newly elected members 2004 . (PDF; 1.58 MB) Halle (Saale), p. 45.

[2] Trauth, Klas, Peters Matzku, Möller, Falk, Debatin, Krammer: Monoclonal antibody-mediated tumor regression by induction of apoptosis . In: Science , Vol. 245, 1989, pp. 301-305, PMID 2787530 .

[3] The associated Fas ligand was cloned in 1993: Suda, Takahashi, Golstein, Nagata: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family . In: Cell , Vol. 75, 1993, pp. 1169-1178

[4] Krammer: Cd95s deathly mission in the immune system . In: Nature , Volume 407, 2000, pp. 789-795

[5] FH Igney, PH Krammer: Tumor counterattack: fact or fiction? In: Cancer Immunol Immunother . , 54 (11), 2005, pp. 1127-1136

[6] Member entry by Peter H. Krammer (with picture and CV) at the German Academy of Natural Scientists Leopoldina , accessed on July 17, 2016.

[7] Directory of members: Peter H. Krammer. Academia Europaea, accessed July 3, 2017 .